Abby Hardy, Author at BioTuesdays

Developments

Protara gets FDA fast track designation for intestinal failure-associated liver disease

Protara Therapeutics’ (NASDAQ:TARA) IV choline chloride received FDA fast track designation for the treatment of intestinal failure-associated liver disease (IFALD). IFALD occurs in patients who have been receiving...

May 26, 2020

Developments

TransMedics reports positive topline results from liver transplant trial

TransMedics Group’s (NASDAQ:TMDX) pivotal Organ Care System (OCS) liver trial, called PROTECT, achieved its primary and secondary effectiveness and safety endpoints. TransMedics’ OCS technology addresses the major...

May 26, 2020

Developments

Cidara doses first patient in Phase 3 rezafungin trial

Cidara Therapeutics (NASDAQ:CDTX) dosed the first patient in its Phase 3 trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. The...

May 21, 2020

Developments

Passage Bio gets rare pediatric disease designation for gangliosidosis

Passage Bio’s (NASDAQ:PASG) PGBM01 received FDA rare pediatric disease designation for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene impair...

May 21, 2020

Developments

Kadmon reports positive topline results from pivotal GvHD trial

Kadmon Holdings (NYSE:KDMN) reported positive topline results from its pivotal trial of KD025 (belumosudil) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of...

May 21, 2020

Developments

Imagin Medical receives functional i/Blue Imaging Systems

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) received functional i/Blue systems from its contract design and development firm, Optel, which will be used to conduct in...

May 21, 2020

Developments

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the fourth dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 225 mg dosing level to be safe and...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Developments

Kane Biotech recommences trading on the OTCQB

Kane Biotech’s (TSX-V:KNE) shares will recommence trading on the OTCQB Venture Market on May 19, 2020. Kane Biotech’s shares have been trading under the Pink Open Market since Feb. 4, 2019. With the upgrade to the...

May 19, 2020

Developments

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) is planning to commence a Phase 2a trial of CRV431 for the treatment of NASH fibrosis in June. The study, called AMBITION, will enroll 18 adults with presumed NASH F2- or F3-stage...

May 19, 2020

Author - Abby Hardy

Protara gets FDA fast track designation for intestinal failure-associated liver disease

TransMedics reports positive topline results from liver transplant trial

Cidara doses first patient in Phase 3 rezafungin trial

Passage Bio gets rare pediatric disease designation for gangliosidosis

Kadmon reports positive topline results from pivotal GvHD trial

Imagin Medical receives functional i/Blue Imaging Systems

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Kane Biotech recommences trading on the OTCQB

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Subscribe